Treatment of influenza virus-related critical illness during continuous renal replacement therapy: take caution with dosing
Main Authors: | Patrick M. Honore, Luc Kugener, Sebastien Redant, Rachid Attou, Andrea Gallerani, David De Bels |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-03-01
|
Series: | Critical Care |
Online Access: | http://link.springer.com/article/10.1186/s13054-020-2813-y |
Similar Items
-
Dosing adjuvant vitamin C in critically ill patients undergoing continuous renal replacement therapy: We are not there yet!
by: Patrick M. Honore, et al.
Published: (2019-01-01) -
No dose adjustment of tigecycline is necessary during continuous renal replacement therapy: we are not sure
by: Patrick M. Honore, et al.
Published: (2020-02-01) -
Adsorption and caspofungin dosing during continuous renal replacement therapy
by: Patrick M. Honore, et al.
Published: (2019-07-01) -
Who may benefit most from future vitamin D intervention trials: do not forget patients on continuous renal replacement therapy
by: Patrick M. Honore, et al.
Published: (2020-04-01) -
Endocan removal during continuous renal replacement therapy: does it affect the reliability of this biomarker?
by: Patrick M. Honore, et al.
Published: (2019-05-01)